Ventyx biosciences announces completion of enrollment of the phase 2 trial of vtx002 in ulcerative colitis and the phase 2 trial of vtx958 in plaque psoriasis

Topline results from the phase 2 trial of vtx002 (s1p1r modulator) in ulcerative colitis and the phase 2 trial of vtx958 (tyk2 inhibitor) in plaque psoriasis are expected in q4 2023 topline results from the phase 2 trial of vtx002 (s1p1r modulator) in ulcerative colitis and the phase 2 trial of vtx958 (tyk2 inhibitor) in plaque psoriasis are expected in q4 2023
VTYX Ratings Summary
VTYX Quant Ranking